Johnson & Johnson

• Johnson & Johnson offers $5.5B to settle baby powder cancer lawsuits

  The New Jersey-based drugmaker has been fighting talc-related lawsuits for more than a decade and said the settlement was a last-ditch effort to put the matter to bed.

  Trending

  Jul 28
  
• Should Canadians still use nasal decongestants? What we know after FDA panel ruling

  The Food and Drug Administration (FDA) ruled Tuesday that a key drug in popular decongestants is ineffective, which one Canadian group of doctors has known for years.

  Canada

  Sep 13, 2023
  
• Advertisement
• New blood cancer therapy approved in the U.S.

  The therapy's approval comes with FDA's "boxed" safety warning, flagging the risk of a type of aggressive immune response and neurologic toxicity.

  Health

  Aug 10, 2023
• Advertisement
• Some kids’ painkillers in short supply, but pharmacists say prescription not needed

  Two Ontario pediatric hospitals say they're facing shortages of common pain relievers amid supply disruptions in some parts of the country.

  Health

  Aug 17, 2022
• Johnson & Johnson to halt worldwide sales of talc-based baby powder in 2023

  The company faces about 38,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos, a known carcinogen.

  Health

  Aug 11, 2022
• Canada won’t limit J&J COVID-19 vaccine access due to rare blood clots: Tam

  Canada's top doctor said Friday that there have been no cases of a rare blood clotting syndrome from Johnson & Johnson's COVID-19 vaccine so far in the country.

  Canada

  May 6, 2022
• U.S. First Nations win $590M from drug companies in opioid epidemic lawsuit settlement

  Under the settlement, Johnson & Johnson agreed to pay $150 million over two years and the three largest U.S. drug distributors will pay nearly $440 million over seven years.

  World

  Feb 2, 2022
• J&J expects COVID-19 vaccine sales boost in 2022 on strong demand

  Johnson & Johnson is expecting that sales of its COVID-19 vaccines could rise to $3.5 billion in 2022, though the total will not account for much of its overall profits.

  Economy

  Jan 25, 2022
• Advertisement
• J&J COVID-19 vaccine protects against breakthrough infections, study says

  Johnson & Johnson said protection against COVID-19 infection from its single-dose vaccine starts to wane only from the fourth month.

  Health

  Jan 6, 2022
• Advertisement
• Single-dose Johnson & Johnson vaccine available in Sask. beginning Wednesday

  The Saskatchewan government announced Tuesday that a supply of the one-dose J&J COVID-19 shot will be administered through multiple SHA clinics on a first-come, first-serve basis.

  Health

  Nov 16, 2021